Please provide your email address to receive an email when new articles are posted on . Postmenopausal women with osteoporosis who received a regimen of three separate, 6-month cycles of daily ...

Please provide your email address to receive an email when new articles are posted on . Lyu and colleagues analyzed electronic medical records data from 151 adults aged at least 45 years identified as ...

Teva Pharmaceutical has announced the US Food and Drug Administration (FDA) approval for Ponlimsi (denosumab-adet) as a ...

BENGALURU, India and BRIDGEWATER, N.J., Sept. 17, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of ...

Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia ® (denosumab), to treat a variety of ...

November 10, 2010 — In advanced breast cancer patients who have bone metastases, the novel biologic denosumab was superior to zoledronic acid in preventing skeletal-related events (SREs) and renal ...

New 2-Year Open-Label Study Shows More Than 90 Percent of Patients Preferred Prolia Injection Every Six Months Over Weekly Oral Alendronate THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen ...

SHANGHAI, April 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Denosumab Injection (trade name: MAIWEIJIAN, R&D ...

A first-of-its-kind osteoporosis drug lowers the risk of bone fractures as well as or better than current medicines, studies in older women and men with prostate cancer suggest. Advisers to the Food ...